RhumbLine Advisers’s Prevail Therapeutics PRVL Stock Holding History
Bought
Maintained
Sold
RhumbLine Advisers's PRVL Position: Q1 2021 in Review
RhumbLine Advisers sold out of Prevail Therapeutics (PRVL) in Q1 2021, closing a stake of 15,258 shares — an estimated $352K sold.
RhumbLine Advisers first reported a position in PRVL in Q2 2020 and held it in 3 quarters. The position peaked at $352K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.
- RhumbLine Advisers reported no remaining Prevail Therapeutics position as of Q1 2021 after selling out during the quarter.
- RhumbLine Advisers sold 15,258 Prevail Therapeutics shares in Q1 2021, an estimated $352K.
- RhumbLine Advisers first reported a position in Prevail Therapeutics in Q2 2020 and held it in 3 quarters.
- RhumbLine Advisers's Prevail Therapeutics position peaked at $352K in Q4 2020.
- 0 funds tracked by Wall St. Rank held Prevail Therapeutics as of Q1 2021.
Based on RhumbLine Advisers's 13F filing for Q1 2021, filed 6 May 2021.